Regorafenib and Nivolumab in Mismatch Repair (MMR) Refractory Colorectal Cancer

February 5, 2026 updated by: H. Lee Moffitt Cancer Center and Research Institute

Phase I Study of Regorafenib and Nivolumab in Mismatch Repair (MMR) Proficient Advanced Refractory Colorectal Cancer

The main purpose of this study is to test the safety, tolerable side effects, and determine the highest tolerable dose of the combination of Regorafenib and Nivolumab. Researchers want to find out if this combination of Regorafenib and Nivolumab can help people with metastatic colorectal cancer with mismatch repair (MMR) proficiency.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

52

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Florida
      • Tampa, Florida, United States, 33612
        • H. Lee Moffitt Cancer Center and Research Institute

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Histologically confirmed diagnosis of colorectal adenocarcinoma
  • Proficient DNA mismatch repair (MMR) or stable microsatellite disease.
  • Participants with the presence of at least one lesion with measurable disease as defined by 10mm in longest diameter for a soft tissue lesions or 15mm in short axis for a lymph node by RECIST 1.1 for response assessment.
  • Participants must have received and progressed through or become intolerant to fluoropyrimidine, irinotecan, oxaliplatin, and bevacizumab, and if K-ras wild type, cetuximab or panitumumab containing therapies. Exceptions may apply.
  • Eastern Cooperative Oncology Group (ECOG) Performance Score 0 or 1
  • Estimated life expectancy over 3 months.
  • Adequate bone marrow, liver and renal function.
  • Participants must not have had chemotherapy, major surgery, monoclonal antibody therapy or experimental therapy within the 21 days prior to the start of regorafenib and nivolumab administration
  • Women of childbearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) performed within 24 hours prior to the start of study drug and then every 4 weeks. Post-menopausal women (defined as no menses for at least 1 year) and surgically sterilized women are not required to undergo a pregnancy test.
  • Participants (men and women) of childbearing potential must agree to use adequate contraception beginning at the signing of the Informed Consent Form (ICF) until at least 5 months for females and 7 months for males after the last dose of study drug
  • Participants must be able to understand and be willing to sign the written informed consent form and be willing and able to comply with scheduled visits, treatment schedule, laboratory testing, and other study requirements.

Exclusion Criteria:

  • Participants with active Central Nervous System (CNS) metastases If CNS metastases are treated and participants are at neurologic baseline for at least 2 weeks prior to enrollment, they will be eligible but will need a Brain MRI prior to enrollment.
  • Uncontrolled hypertension (systolic pressure >140 mm Hg or diastolic pressure > 90 mm Hg [NCI-CTCAE v5.0] on repeated measurement) despite optimal medical management.
  • Active or clinically significant cardiac disease.
  • Women who are pregnant or breast-feeding
  • Prior therapy with regorafenib, anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell costimulation or checkpoint pathways).
  • Previous or concurrent cancer within 3 years prior to treatment start EXCEPT for curatively treated cervical cancer in situ, non-melanoma skin cancer, superficial bladder tumors [Ta (non-invasive tumor), Tis (carcinoma in situ) and T1 (tumor invades lamina propria)].
  • Active autoimmune disease that has required systemic treatment in the past 2 years. Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
  • Ascites, pleural effusion, or pericardial fluid requiring drainage in the last 4 weeks
  • Participants with phaeochromocytoma
  • Ongoing infection > Grade 2
  • Presence of a non-healing wound, or bone fracture.
  • Renal failure requiring hemo-or peritoneal dialysis.
  • Seizure disorder requiring medication.
  • Interstitial lung disease with ongoing signs and symptoms at the time of informed consent.
  • Pleural effusion or ascites that causes respiratory compromise.
  • Any condition which, in the investigator's opinion, makes the subject unsuitable for trial participation.
  • Known or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial.
  • Persistent proteinuria ≥ Grade 3
  • History of organ allograft
  • Participants requiring warfarin or equivalent vitamin K antagonists (e.g. phenprocoumon)
  • Participants with a condition requiring a strong CYP3A4 inhibitors or strong CYP3A4 inducers.
  • Unresolved toxicity higher than CTCAE grade 1 attributed to any prior therapy or procedure, excluding alopecia.
  • Any hemorrhage or bleeding event ≥ NCI CTCAE Grade 3 within 4 weeks prior to start of study medication.
  • Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results.
  • Participants with an arterial thrombotic or thromboembolic event within 6 months of informed consent.
  • Known history of human immunodeficiency virus (HIV) infection or current chronic or active hepatitis B or C infection.
  • Child-Pugh B cirrhosis (or worse) or a history of hepatic encephalopathy
  • History of stroke or intracranial hemorrhage within 6 months prior to enrollment.
  • Major surgery or a wound that has not fully healed within 4 weeks of enrollment.
  • Participants requiring concurrent anti-cancer therapy other than study treatment.
  • Participants requiring hormonal therapy during the study or within 2 weeks of first study enrollment.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Sequential Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Regorafenib and Nivolumab Combination - Escalation
Dose Escalation: To find the dose of regorafenib that can be safely given with nivolumab in patients with advanced, refractory colorectal cancers.
Drug: Regorafenib
Regorafenib orally 80 mg daily for 21 days (3 weeks on, 1 week off).
Other Names:
  • Stivarga
Drug: Nivolumab
Nivolumab 240 mg administered intravenously every 2 weeks.
Other Names:
  • OPDIVO
Experimental: Regorafenib and Nivolumab Combination - Expansion
Dose Expansion: To find the effect on tumor of the combination of regorafenib and nivolumab.
Drug: Regorafenib
Regorafenib orally 80 mg daily for 21 days (3 weeks on, 1 week off).
Other Names:
  • Stivarga
Drug: Nivolumab
Nivolumab 240 mg administered intravenously every 2 weeks.
Other Names:
  • OPDIVO

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Maximum Tolerated Dose
Time Frame: Up to 12 months
To determine the maximum tolerated dose of Regorafenib in combination with Nivolumab in advanced, refractory colorectal cancers.
Up to 12 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Response Rate
Time Frame: Every 2nd cycle (Cycles are 28 days) up to 12 months
To access response rate using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Every 2nd cycle (Cycles are 28 days) up to 12 months
Overall Survival (OS)
Time Frame: Up to 24 months after conclusion of treatment
Occurrence of Overall Survival
Up to 24 months after conclusion of treatment
Frequency and Severity of Adverse Events
Time Frame: Up to 12 months
To evaluate the frequency and severity of adverse events and tolerability of the combination regimen.
Up to 12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Collaborators

Bristol-Myers Squibb

Investigators

  • Principal Investigator: Dae W Kim, MD, H. Lee Moffitt Cancer Center and Research Institute

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 23, 2018

Primary Completion (Actual)

September 1, 2021

Study Completion (Actual)

January 18, 2024

Study Registration Dates

First Submitted

October 15, 2018

First Submitted That Met QC Criteria

October 18, 2018

First Posted (Actual)

October 19, 2018

Study Record Updates

Last Update Posted (Actual)

February 9, 2026

Last Update Submitted That Met QC Criteria

February 5, 2026

Last Verified

February 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • MCC-19581

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Metastatic Colorectal Cancer

Clinical Trials on Regorafenib

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zambia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe